- Home
- AMZE vs INAB Comparison
AMZE vs INAB Comparison
Compare AMZE & INAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AMZE
- INAB
- Stock Information
- Founded
- AMZE 2019
- INAB 2016
- Country
- AMZE United States
- INAB United States
- Employees
- AMZE N/A
- INAB N/A
- Industry
- AMZE Beverages (Production/Distribution)
- INAB Biotechnology: Pharmaceutical Preparations
- Sector
- AMZE Consumer Staples
- INAB Health Care
- Exchange
- AMZE Nasdaq
- INAB Nasdaq
- Market Cap
- AMZE 12.3M
- INAB 10.6M
- IPO Year
- AMZE 2021
- INAB 2021
- Fundamental
- Price
- AMZE $0.81
- INAB $1.92
- Analyst Decision
- AMZE
- INAB Strong Buy
- Analyst Count
- AMZE 0
- INAB 2
- Target Price
- AMZE N/A
- INAB $108.00
- AVG Volume (30 Days)
- AMZE 171.8K
- INAB 64.5K
- Earning Date
- AMZE 11-14-2025
- INAB 11-10-2025
- Dividend Yield
- AMZE N/A
- INAB N/A
- EPS Growth
- AMZE N/A
- INAB N/A
- EPS
- AMZE N/A
- INAB N/A
- Revenue
- AMZE $1,054,111.00
- INAB N/A
- Revenue This Year
- AMZE $6,741.66
- INAB N/A
- Revenue Next Year
- AMZE $100.61
- INAB N/A
- P/E Ratio
- AMZE N/A
- INAB N/A
- Revenue Growth
- AMZE N/A
- INAB N/A
- 52 Week Low
- AMZE $0.82
- INAB $1.82
- 52 Week High
- AMZE $25.07
- INAB $12.53
- Technical
- Relative Strength Index (RSI)
- AMZE 27.46
- INAB 35.95
- Support Level
- AMZE $1.00
- INAB $1.82
- Resistance Level
- AMZE $0.95
- INAB $2.15
- Average True Range (ATR)
- AMZE 0.15
- INAB 0.09
- MACD
- AMZE -0.02
- INAB -0.02
- Stochastic Oscillator
- AMZE 1.61
- INAB 28.15
About AMZE Amaze Holdings Inc. Common Stock
Amaze Holdings Inc is engaged in producer of low carb, low calorie, premium wines in the United States. The company offers bold, crisp, and creamy wines that embody health, warmth, and a deeper connection to wellness and an active lifestyle. The company currently sell seven proprietary varietals: Cabernet Sauvignon, Pinot Noir, Chardonnay, Sauvignon Blanc, Rose, Sparkling Rose, and a limited Reserve Napa Cabernet Sauvignon.
About INAB IN8bio Inc.
IN8bio Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of gamma-delta T cell product candidates for solid and liquid tumors, by employing allogeneic, autologous, and genetically modified gamma-delta T cells. Its product candidates include INB-400, for the treatment of newly diagnosed glioblastoma, or GBM, INB-100 for the treatment of patients with high-risk leukemias undergoing hematopoietic stem cell transplantation, and other product candidates such as INB-200, INB-300, and INB-500.